Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H, Furukawa K
First Department of Surgery, Fukui Medical School, Fukui, Japan.
J Clin Oncol. 1996 Apr;14(4):1122-7. doi: 10.1200/JCO.1996.14.4.1122.
To determine the expression of the CD44 variant containing a variant exon 8 to 10 product (CD44v8-10) in colorectal cancer and to evaluate its prognostic value.
CD44v8-10 was studied in resected tumors and normal mucosae obtained from 215 colorectal cancer patients (118 colon cancer and 97 rectal cancer). The expression of CD44v8-10 was analyzed immunohistochemically using the anti-CD44v8-10 monoclonal antibody (mAb) 44-1V.
One hundred of 215 cancer tissues expressed CD44v8-10. Positive staining was intense mainly on the cell membranes. There was no significant correlation between expression of CD44v8-10 and histologic type, primary tumor, lymphatic invasion, venous invasion, or peritoneal invasion. There were significant correlations between CD44v8-10 immunoreactivity and both lymph node and hematogenous metastasis. Patients with CD44v8-10-positive tumors had a greater relative risk of death compared with those whose tumors were CD44v8-10-negative. Among 169 patients who underwent curative resection, CD44v8-10 expression correlated with a high recurrence rate. The 5- and 10-year survival rates were 90.3% of patients with CD44v8-10-negative tumors, and 72.1% and 58.0% of those with CD44v8-10-positive tumors, respectively; these differences between the two groups of patients were significant (P < .01). In multivariate analysis using the Cox regression model, CD44v8-10 expression emerged as an independent prognostic indicator.
The results suggest that CD44v8-10 plays a role in metastasis of colorectal cancer, and tha CD44v8-10 expression may be a biologic marker of prognostic significance.
确定包含可变外显子8至10产物的CD44变体(CD44v8 - 10)在结直肠癌中的表达,并评估其预后价值。
对215例结直肠癌患者(118例结肠癌和97例直肠癌)切除的肿瘤及正常黏膜组织进行CD44v8 - 10研究。使用抗CD44v8 - 10单克隆抗体(mAb)44 - 1V通过免疫组织化学分析CD44v8 - 10的表达。
215例癌组织中有100例表达CD44v8 - 10。阳性染色主要集中在细胞膜上。CD44v8 - 10的表达与组织学类型、原发肿瘤、淋巴浸润、静脉浸润或腹膜浸润之间无显著相关性。CD44v8 - 10免疫反应性与淋巴结转移和血行转移均存在显著相关性。与CD44v8 - 10阴性肿瘤患者相比,CD44v8 - 10阳性肿瘤患者的相对死亡风险更高。在169例行根治性切除术后的患者中,CD44v8 - 10表达与高复发率相关。CD44v8 - 10阴性肿瘤患者的5年和10年生存率分别为90.3%,而CD44v8 - 10阳性肿瘤患者分别为72.1%和58.0%;两组患者之间的这些差异具有统计学意义(P < 0.01)。在使用Cox回归模型的多因素分析中,CD44v8 - 10表达是一个独立的预后指标。
结果表明CD44v8 - 10在结直肠癌转移中起作用,且CD44v8 - 10表达可能是具有预后意义的生物学标志物。